DESTINY-Breast03研究作为ENHERTU的首个随机对照、III期临床试验,旨在评估ENHERTU对比T-DM1用于既往接受过曲妥珠单抗和紫杉类治疗的HER2阳性晚期乳腺癌的疗效与安全性,研究入组了61%帕妥珠单抗经治和22%脑转移患者,ESMO大会和NEJM同时公布该研究成果,数据显示,截止2021年5月数据分析时,ENHERTU组中位随访16个月,T-...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast canc...
AstraZeneca and Daiichi Sankyo’s ENHERTU®(fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ o...
Detailed positive results from an interim analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® demonstrated clinically meaningful tumor responses in previously-treated patients with HER2-mutant unres...
直至新型ADC药物 fam-trastuzumab deruxtecan-nxki(Enhertu,此前称为T-DXd或DS-8201a)的问世,打破了只有HER2阳性乳腺癌才能从抗HER2靶向治疗中获益的传统认知,HER2低表达的精准治疗时代来临。 ▲ADC药物Enhertu的作用机制:Enhertu与肿瘤细胞表面的HER2蛋白(浅绿色)结合,然后通过细胞内吞作用进入细胞内,随后药物的...
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2...
Li B T, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.NEJM. 2022; 386:241-251. Dr. Li has provided uncompensated advisory services to AstraZeneca and Daiichi Sankyo. #...